
|Videos|June 19, 2017
Dr. Tripathy Discusses Immunotherapy in HER2+ Breast Cancer
Author(s)Debu Tripathy, MD,
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.
Advertisement
Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.
With many mature data being presented in the near future, Tripathy says that trials with combinations of standard chemotherapy and immunotherapy, trastuzumab (Herceptin) and pertuzumab (Perjeta), are promising.
On the other hand, Tripathy adds, estrogen receptor-positive/HER2-negative breast cancers have been shown to be less immunogenic.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































